Clinical Trials
38 trialsEPCOREâ„¢ NHL-2
Genmab
Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Artiva Biotherapeutics, Inc.
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Big Ten Cancer Research Consortium
FIL_A-BEGEV
Fondazione Italiana Linfomi - ETS
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Emory University
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide
Thomas Jefferson University
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
ZUMA-1
Gilead Sciences
FUSION NHL 001
Celgene
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)
Arbeitsgemeinschaft medikamentoese Tumortherapie
Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Celgene
Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia
Aptevo Therapeutics
BeGeRN
St. Petersburg State Pavlov Medical University
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
Weill Medical College of Cornell University
GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
St. Petersburg State Pavlov Medical University
SGN+Benda
Columbia University
NB001
St. Petersburg State Pavlov Medical University
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
National Cancer Institute (NCI)
Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma
Swiss Cancer Institute
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Seagen Inc.
TREC
University of Washington
CLL2P
German CLL Study Group
LENA-BERIT
Lund University Hospital
Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
BERT
Johannes Gutenberg University Mainz
LEBEN
GiovanniPascale
Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)
Kantonsspital Aarau
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
Jichi Medical University
Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Bendamustine in Acute Leukemia and MDS
M.D. Anderson Cancer Center
Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)
Southern Europe New Drug Organization
Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Charite University, Berlin, Germany